Exelixis | EXEL - Debt


Exelixis reported $176.46M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Bayer EUR 39.39B 1.31B Mar/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Exelixis USD 176.46M 3.38M Sep/2025
Genmab DKK 148M 5M Jun/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 734M 7M Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sanofi EUR 21.76B 530M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Xencor USD 69.27M 1.34M Sep/2025